1 day Ago By ABMN Staff
IO Biotech ( NASDAQ:IOBT – Get Free Report ) ‘s stock had its “buy” rating restated by HC Wainwright in a report issued on Monday, Benzinga reports. They currently have a $12.00 target price on the stock.
Several other analysts also recently commented on IOBT. Morgan Stanley raised their target price on shares of IO Biotech from $4.00 to $6.
00 and gave the stock an “overweight” rating in a report on Monday. Piper Sandler reissued an “overweight” rating and set a $10.00 price objective on shares of IO Biotech in a research report on Tuesday, September 3rd.
Read Our Latest Stock Report on IOBT IO Biotech Stock Up 53.5 % IO Biotech ( NASDAQ:IOBT – Get Free Report ) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.
31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.04.
On average, equities research analysts expect that IO Biotech will post -1.2 earnings per share for the current fiscal year. Insider Transactions at IO Biotech In other news, major shareholder Holdings A/S Novo sold 51,522 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th.
The shares were sold at an average price of $1.33, for a total transaction of $68,524.26.
Following the completion of the transaction, the insider now directly owns 4,377,927 shares of the company’s stock, valued at approximately $5,822,642.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink .
2.30% of the stock is owned by insiders. Institutional Investors Weigh In On IO Biotech Several institutional investors and hedge funds have recently added to or reduced their stakes in IOBT.
XTX Topco Ltd raised its stake in shares of IO Biotech by 67.4% during the 2nd quarter. XTX Topco Ltd now owns 26,555 shares of the company’s stock worth $31,000 after purchasing an additional 10,688 shares in the last quarter.
Renaissance Technologies LLC grew its stake in shares of IO Biotech by 8.1% in the second quarter. Renaissance Technologies LLC now owns 180,800 shares of the company’s stock valued at $212,000 after buying an additional 13,600 shares in the last quarter.
Finally, PFM Health Sciences LP increased its holdings in IO Biotech by 73.0% during the fourth quarter. PFM Health Sciences LP now owns 2,341,107 shares of the company’s stock worth $4,401,000 after buying an additional 987,654 shares during the last quarter.
54.76% of the stock is owned by institutional investors. About IO Biotech ( Get Free Report ) IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform.
The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. Read More Receive News & Ratings for IO Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IO Biotech and related companies with MarketBeat.com's FREE daily email newsletter .
.
